CannAssure Therapeutics Overview
Cannassure develops and commercializes a wide range of effective, high-quality, affordable medical cannabis products and pharmaceutical cannabinoid medicines designed to enhance treatment and improve the quality of life for people worldwide. The company ensures the highest standards by facilitating a holistic integrated production system, including a clean and controlled and advanced indoor aeroponic grow facility and an extraction and processing facility, along with scientifically advanced research and development. Cannassure operates in accordance with IMC-GAP standards, testing both its unprocessed cultivated cannabis and its manufactured products at different stages of production to ensuring purity, effectiveness, stability, and consistency for the duration of the products shelf life. Cannasure is a spinoff of food manufacturer Solbar Food Technologies, with 60 years of applied industrial expertise and know-how. Solbar is the majority shareholder in the company.
Latest News
growth-positive
קאנשור משיגה בלעדיות על זן פרויד
קנאשור תראפיוטיקס, a leading indoor company in Israel, has signed an exclusive agreement for the cultivation, marketing, and sale of the successful Freud Super Ego strain. The agreement covers all products based on the Freud strain or its flower. The company is in the process of expanding its cultivation of the strain, which began at its facility in Ashdod. RCK, a technology developer for the development and cultivation of new cannabis strains, is closely collaborating with קנאשור תראפיוטיקס. The agreement is seen as an important milestone in the fruitful cooperation between the companies over the past two years and contributes to the development strategy of RCK through partnerships with quality growers.
PartnersExpand
growth-positive
קנאשור ו- CiiTECH ישווקו את שמני המותג Provacan בישראל
Provacan, a popular brand in the UK, is expected to begin its marketing in the first quarter of 2022. Provacan has announced a partnership agreement with CiiTECH for the production and distribution of cannabis oils in Israel. The cannabis consumer market in Israel is growing steadily, and the partnership aims to educate users about the effectiveness of CiiTECHs oils compared to smoking flowers. The companies will provide courses for Provacan ambassadors and users to promote the use of CiiTECH and Provacan products. The partnership is expected to bring value to both companies and the cannabis market in Israel.
Partners
יו"ר קאנשור עידו נחושתן עוזב. האם זה קשור לתנאי השכר שלו?
growth-positive
Cannassure was granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority
Cannassure Therapeutics has been granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority. The companys innovative technology allows for the provision of an exact amount of active ingredients through oral ingestion, using a high concentration of cannabinoids or medical cannabis extract. This new delivery system provides alternative methods of administration and swallowable products, expanding access to cannabis-based treatments for new patient populations. The patent approval gives Cannassure a competitive advantage in the global market for swallowable cannabis products. The company plans to seek regulatory approval for testing the effectiveness of their products for pain relief in humans and continue developing and commercializing a wide range of innovative medical cannabis products.
CustomersInvestment
growth-positive
DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology
DanCann Pharma announces that its strategic partner, Cannassure Therapeutics, has signed an exclusive licensing agreement with Lipidor AB for the use of AKVANO® technology in medicinal cannabis products. DanCann Pharma is the exclusive distributor of Cannassures product portfolio in Scandinavia. The agreement allows Cannassure to develop products for the non-prescription and prescription markets, while Lipidor retains the right to develop cannabis-related products in other indications. The market for topical therapies in the covered indications is expected to exceed USD 50 billion by 2027. DanCann Pharma also has a distribution agreement with Cannassure to expand its product portfolio in cannabinoid-based pharmaceuticals. The company plans to submit its first product approval application in early 2021. The CEOs of both DanCann Pharma and Cannassure express excitement about the partnership and the potential for innovative cannabis treatments.
PartnersCustomers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $3.44M |
| Last funding | $235K |
| Stage | Public |
| Rounds | 2 |
| Investors | 0 |
Team Members
4
Employees: 1-10
Web & Social Links
| Website | www.cannassure.life/ |
| Careers | Careers page |
Locations
HaHadarim Street 2, Ashdod, Israel
Photos & Videos
3 item(s)
CannAssure Therapeutics Business
Business models
B2B2C, B2B
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentMedical CannabisTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatientsCore Technology
BiologicalsHerbalsTags (13)
pharmaceuticalsseedscannabismedical-productsmedical-cannabisdrug-deliverywomen-healthpatientsindoor-farmingtopical-treatmentdermatologyoral-drugsanti-inflammatoryGeographic Markets
FranceSwedenDenmarkIsraelNorwayFinlandCannAssure Therapeutics Financials
$3.44M
Total funding
—
Capital raised
$235K
Last funding
Public
Funding stage
2
Total rounds
0
Investors
Non-Equity Funding
GrantEvent
Aug 2020
$235K
Israel Innovation Authority
Public Offering / Exit
POEvent
Dec 2018
Undisclosed
CannAssure Therapeutics Lifecycle
All Events
GrantEvent
Aug 2020
$235K
Israel Innovation Authority
POEvent
Dec 2018
Undisclosed
CannAssure Therapeutics News
14 articles
growth-positive
קאנשור משיגה בלעדיות על זן פרויד
קנאשור תראפיוטיקס, a leading indoor company in Israel, has signed an exclusive agreement for the cultivation, marketing, and sale of the successful Freud Super Ego strain. The agreement covers all products based on the Freud strain or its flower. The company is in the process of expanding its cultivation of the strain, which began at its facility in Ashdod. RCK, a technology developer for the development and cultivation of new cannabis strains, is closely collaborating with קנאשור תראפיוטיקס. The agreement is seen as an important milestone in the fruitful cooperation between the companies over the past two years and contributes to the development strategy of RCK through partnerships with quality growers.
PartnersExpand
growth-positive
קנאשור ו- CiiTECH ישווקו את שמני המותג Provacan בישראל
Provacan, a popular brand in the UK, is expected to begin its marketing in the first quarter of 2022. Provacan has announced a partnership agreement with CiiTECH for the production and distribution of cannabis oils in Israel. The cannabis consumer market in Israel is growing steadily, and the partnership aims to educate users about the effectiveness of CiiTECHs oils compared to smoking flowers. The companies will provide courses for Provacan ambassadors and users to promote the use of CiiTECH and Provacan products. The partnership is expected to bring value to both companies and the cannabis market in Israel.
Partners
יו"ר קאנשור עידו נחושתן עוזב. האם זה קשור לתנאי השכר שלו?
growth-positive
Cannassure was granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority
Cannassure Therapeutics has been granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority. The companys innovative technology allows for the provision of an exact amount of active ingredients through oral ingestion, using a high concentration of cannabinoids or medical cannabis extract. This new delivery system provides alternative methods of administration and swallowable products, expanding access to cannabis-based treatments for new patient populations. The patent approval gives Cannassure a competitive advantage in the global market for swallowable cannabis products. The company plans to seek regulatory approval for testing the effectiveness of their products for pain relief in humans and continue developing and commercializing a wide range of innovative medical cannabis products.
CustomersInvestment
growth-positive
DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology
DanCann Pharma announces that its strategic partner, Cannassure Therapeutics, has signed an exclusive licensing agreement with Lipidor AB for the use of AKVANO® technology in medicinal cannabis products. DanCann Pharma is the exclusive distributor of Cannassures product portfolio in Scandinavia. The agreement allows Cannassure to develop products for the non-prescription and prescription markets, while Lipidor retains the right to develop cannabis-related products in other indications. The market for topical therapies in the covered indications is expected to exceed USD 50 billion by 2027. DanCann Pharma also has a distribution agreement with Cannassure to expand its product portfolio in cannabinoid-based pharmaceuticals. The company plans to submit its first product approval application in early 2021. The CEOs of both DanCann Pharma and Cannassure express excitement about the partnership and the potential for innovative cannabis treatments.
PartnersCustomers
growth-positive
קנאשור השלימה הנפקת מניות בהיקף של כ-10 מיליון שקל
Medical cannabis company Kanashur has completed a stock offering worth approximately 10 million NIS. The company received excess demand of 1.5 times the offering amount, totaling around 17 million NIS. The proceeds from the offering will support the companys ongoing activities. Kanashur also announced sales forecasts of approximately 34 million NIS for 2021 and is in advanced discussions with several growers in Israel for processing, manufacturing, and packaging services. Additionally, the company is working on an exclusive license agreement for the global use of Lipidor technology combined with cannabis and cannabinoids for the production of products. Kanashur recently completed a successful feasibility study for a medical device based on cannabinoids for local treatment of inflammatory skin diseases.
InvestmentExpand
growth-positive
Cannasure and DanCann Pharma sign an exclusive distribution agreement for Denmark, Norway, Sweden and Finland
Cannassure Therapeutics has signed an exclusive distribution agreement with DanCann Pharma to distribute its medical cannabis products in Denmark, Norway, Sweden, and Finland. The agreement aligns with Cannassures strategy of expanding its business and pipeline. The CEO of DanCann Pharma expressed excitement about the partnership and the opportunity to provide patients with alternative treatment options. Cannassure is a leading developer and provider of medical cannabis products, while DanCann Pharma is a Danish pharmaceutical biotechnology company focused on cannabinoids. The specific products and branding will be determined mutually by both parties. The distribution agreement is expected to benefit both companies and patients in Scandinavia, with the products set to launch in 2021.
Partners
growth-positive
קנאשור ייצאה לראשונה לצרפת שמן קנאביס
Israeli medical cannabis company, Cannasure, has exported its Cannasure Drops to France for the first time as part of a pilot program for medical cannabis. The company has also signed a memorandum of understanding with a French pharmaceutical company for collaboration in the pilot program. The pilot program in France will be conducted by the National Agency for Medicines Safety (ANSM), and the cannabis oils sent will be tested in ANSM laboratories. Cannasure Drops are based on botanical extracts from Cannasures facility and are intended for sublingual use. The company sees this export as a significant milestone and a step towards its development in Europe.
Partners
growth-positive
Successful completion of feasibility study for the development of topical medical cannabis products based on AKVANO® technology
Cannassure Therapeutics has successfully completed a feasibility study for the development of topical medical cannabis products for the treatment of skin inflammation. The study was conducted in collaboration with Lipidor AB, a Swedish topical drug development company. The development project is partially funded by the Israeli Innovation Authority. The product under development combines cannabinoids with Lipidors AKVANO® technology for localized administration and optimal penetration into the skin. Cannassure intends to negotiate an exclusive global license for the use of Lipidors technology. The global market for psoriasis treatment products is expected to reach $21.1 billion by 2021. Cannassures focus on developing innovative medical cannabis products aligns with its strategy.
PartnersInvestment
growth-positive
Novolog Logistics Will Distribute Cannassure's Products in Israel - Cannassure Therapeutics
Cannassure has selected Novolog Logistics to distribute their medical cannabis products to pharmacies and medical cannabis dispensaries in Israel. This distribution agreement is a milestone for Cannassures goals and product delivery in Israel.
Partners
growth-positive
Cannassure Therapeutics Ltd and Lipidor AB Enter a Feasibility Study and Licence Option Agreement for Development and Sales of Topical Medical Cannabis Products Based on AKVANO Technology
Cannassure Therapeutics has signed an agreement with Lipidor AB for the joint development of topical medical cannabis products. The agreement involves evaluating the feasibility of incorporating active pharmaceutical ingredients from the cannabis plant in Lipidors proprietary drug delivery platform technology. If the feasibility study is successful, Cannassure will have the option to enter an exclusive global license for the use of Lipidors technology. The joint ambition is to introduce innovative products for topical treatments in the growing global market for medical cannabis. The feasibility study is expected to conclude in Q3 2020.
Partners
growth-positive
Senior Teva R&D Executive Joins Cannabis Company Cannassure
Former Teva Pharmaceutical executive Yafit Stark has joined the scientific advisory committee of Cannassure Therapeutics. Starks knowledge and experience will help Cannassure establish itself as a leader in research and development. Cannassure is currently setting up an indoor cannabis greenhouse in Israel and has purchased 12,000 plants from Israeli cannabis company RCK. The company has also received a grant from the Israel Innovation Authority for a CBD extraction venture and expects to start selling oils and extracts in Q1 2020.
PartnersInvestment
growth-positive
Cannassure Therapeutics Announces Strategic Partnership With Cannika Holdings
Cannassure Therapeutics announces its collaboration with Cannika Holdings, an agritech incubator specializing in cannabis innovation. The collaboration will provide medical cannabis start-ups with a complete R&D ecosystem to advance cannabis-related initiatives. Cannassure will offer its facilities and expertise to support early-stage cannabis initiatives. Cannika will establish an independent fully licensed R&D facility with the partnership. Cannassure is a subsidiary of Solbar Food Technologies and holds all the approvals required for establishing a vertically integrated medical cannabis operation.
Partners
growth-positive
https://www.jpost.com/jpost-tech/cannassure-from-soybean-extraction-to-medical-cannabis-575141
Cannassure Therapeutics, an Ashdod-based company, is constructing a state-of-the-art indoor cannabis growing facility. The company, an offshoot of Solbar Food Technologies, has expertise in botanical extraction from its soybean extraction business. They are focusing on producing high-quality cannabis oil extractions using indoor growing methods, which provide consistency and stability. Cannassure has signed a strategic distribution agreement with Hadassah Medical to become their exclusive supplier of medical cannabis oil. While waiting for the approval of medical cannabis exports in Israel, Cannassure is exploring other European locations for potential operations and exports.
PartnersCustomers
CannAssure Therapeutics Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 8 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
CannAssure Therapeutics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | founding month, funding rounds, markets, not claimed |
| BI Verification | Natalia Golczar |
| Registrar ID | 515761138 |
| Crunchbase | cannassure-therapeutics |
| Phone | +97223122018 |
| Creator | Adam Odesser |
| Creator email | adamodesser10@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-08T00:00:00.000Z |
| Created | 2018-05-27T00:00:00.000Z |
| Status detail | Public on TASE on Dec, 2018; |